Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Immunol Rev. 2023 Nov;320(1):100-119. doi: 10.1111/imr.13273. Epub 2023 Sep 11.
Digestive tract cancers (DTC) belong to the most investigated family of tumors. The incidence, prevalence, and mortality rate of DTC remain high, especially for patients with pancreatic cancer. Even though immunotherapy such as immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid cancer types, ICI are still restricted to a very small group of patients and seem to be more efficacious in combination with chemotherapy. Cellular immunotherapy such as CAR T-cell therapy has entered clinical routine in hematological malignancies with outstanding results. There is growing interest on translating this kind of immunotherapy and success into patients with solid malignancies, such as DTC. This review attempts to describe the major advances in preclinical and clinical research with CAR T cells in DTC, considering the most relevant hurdles in each subtype of DTC.
消化道癌（DTC）属于最受研究关注的肿瘤家族之一。DTC 的发病率、患病率和死亡率仍然很高，尤其是胰腺癌患者。尽管免疫疗法，如免疫检查点抑制剂（ICI）已经彻底改变了实体瘤的治疗方法，但 ICI 仍然仅限于极少数患者，并且似乎与化疗联合使用更有效。CAR T 细胞疗法等细胞免疫疗法在血液恶性肿瘤的临床实践中取得了显著的成果。人们越来越关注将这种免疫疗法及其成功应用于实体恶性肿瘤，如 DTC。本综述试图描述 CAR T 细胞在 DTC 中的临床前和临床研究的主要进展，同时考虑到 DTC 各亚型中最相关的障碍。
